Abivax (ABVX) Liabilities and Shareholders Equity (2021 - 2026)
Abivax (ABVX) posted quarterly Liabilities and Shareholders Equity of $640.6 million for Q1 2026, up 264.78% year-over-year from $175.6 million in Q1 2025, and down 5.83% quarter-over-quarter from $680.2 million in Q4 2025.
Abivax (ABVX) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Abivax's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $640.6 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 264.78% year-over-year to $640.6 million; the TTM figure through Mar 2026 stood at $2.2 billion (up 216.36% YoY), while the FY2025 annual figure was $680.2 million, up 210.2% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $640.6 million, down from $680.2 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $762.3 million in Q3 2025, with the low at $77.1 million in Q4 2022.
- The 5-year median for Liabilities and Shareholders Equity is $306.4 million (2024), against an average of $372.1 million.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity jumped 356.58% in 2023, then slumped 55.8% in 2025.
- Abivax's Liabilities and Shareholders Equity stood at $77.1 million in 2022, then surged by 356.58% to $351.9 million in 2023, then plunged by 37.69% to $219.3 million in 2024, then surged by 210.2% to $680.2 million in 2025, then declined by 5.83% to $640.6 million in 2026.
- Business Quant data shows ABVX's Liabilities and Shareholders Equity at $640.6 million in Q1 2026, $680.2 million in Q4 2025, and $762.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | 640.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 640.56 Mn |
| Dec 31, 2025 | 680.20 Mn |
| Sep 30, 2025 | 762.28 Mn |
| Jun 30, 2025 | 135.43 Mn |
| Mar 31, 2025 | 175.60 Mn |
| Dec 31, 2024 | 219.28 Mn |
| Jun 30, 2024 | 306.37 Mn |
| Dec 31, 2023 | 351.90 Mn |
| Dec 31, 2022 | 77.07 Mn |
| Dec 31, 2021 | 124.96 Mn |